OAK Shares Oakridge International Limited
ASX · ASXLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Clinical-stage biotech exposure provides milestone-driven upside but remains highly speculative and dilution-sensitive.
Signal breakdown
- ▸Pipeline milestone potential
- ▸Above 50-day MA (+12.99%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.87× average — accumulation
Is OAK a buy right now?
Trend: OAK is trading above the 50-day average (+14.29%), RSI 26 — oversold territory, with a 3-month return of +0.00%.
Valuation & quality: Oakridge International Limited trades on price-to-book 1.86; fundamentals show net margin 3.2%, return on equity 9.6%, revenue growth 24.7% year on year.
Our screen: BUY (score 3) — Clinical-stage biotech exposure provides milestone-driven upside but remains highly speculative and dilution-sensitive.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.00% | +50.00% | +0.00% | -22.20% | +14.30% | -25.00% | +33.30% | +0.00% |
Fundamentals
Technical signals
About Oakridge International Limited
Oakridge International Limited, together with its subsidiaries, engages in the sale of professional healthcare technology equipment and solutions to healthcare facilities.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.